Does glycyrrhizin enhance therapeutic activity of a colon-specific methylprednisolone prodrug against experimental colitis?
Co-administration of GCZ, a reduction inhibitor, may be a plausible strategy to reduce the therapeutic loss of MP produced from MPS in the large intestine, thus improving the therapeutic property of the prodrug against inflammatory bowel disease.
Our data suggest a protective role for Cx3cl1/Cx3cr1 cross-talk in prion disease.